ArticleCureus2025
Life-Threatening Steroid-Refractory Colitis Following One Cycle of Neoadjuvant Immunotherapy and Chemotherapy for Early Triple-Negative Breast Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis. Neoadjuvant chemotherapy combined with immunotherapy is the standard of care for stage 2-3 breast cancer. This case study describes the clinical history of one patient who experienced profound immune-related adverse events, specifically severe colitis, hepatitis and keratitis following one cycle of neoadjuvant chemotherapy and immunotherapy. The patient was hospitalised and then transferred to a tertiary cancer centre. She needed intensive treatment to treat the colitis, total parenteral nutrition (TPN), three different immunosuppressant drugs, antibiotics, antivirals, and supportive treatment. Breast surgery was performed whilst she was an inpatient, and she did not receive further systemic treatment. In order to avoid significant treatment-related morbidity, better biomarkers predicting immunotherapy toxicity and response are needed to help decide who will benefit from upfront surgery vs. neoadjuvant chemotherapy with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.